Adicet Bio Inc. (NASDAQ:ACET) saw a downside of -4.68% to close Monday at $2.24 after subtracting -$0.11 on the day. The 5-day average trading volume is 478,180 shares of the company’s common stock. It has gained $2.65 in the past week and touched a new high 1 time within the past 5 days. An average of 526,775 shares of the company has been traded in the last 20 days, and the 50-day average volume stands at 1,021,800.
ACET’s 1-month performance is -30.43% or -$0.98 on its low of $2.11 reached on 08/07/23. The company’s shares have touched a 52-week low of $1.98 and high of $21.87, with the stock’s rally to the 52-week high happening on 02/02/23. YTD, ACET has lost -74.94% or -$6.70 and has reached a new high 3 times. However, the current price is down -89.76% from the 52-week high price.
Insider Transactions
ACET stock investors last saw insider trading activity on Jun 30.Healey Don (Chief Technology Officer) most recently sold 4,533 shares at $7.57 per share on Feb 15. This transaction cost the insider $34,327. Chief Technology Officer, Healey Don, sold 10,467 shares at a price of $7.98 on Feb 10. Then, on Nov 10, President & CEO Schor Chen sold 30,000 shares at a price of $20.06 per share. This transaction amounted to $601,920.
Valuation Metrics
ACET stock has a beta of 1.94. Moving on to other valuation ratios, the price-to-book (PB) in the most recent quarter is 0.36.
Adicet Bio Inc.’s quick ratio for the recent period was 13.00, with the current ratio over the same period at 13.00. The trailing 12-month EBITDA margin is -270.28%. The firm’s gross profit as reported stood at $97.54 million against revenue of $24.99 million.
Earnings Surprise
Net income grew 114.96% to -$30.88 million, while revenue of -$29.87 million was 3.27% off the previous quarter. EBITDA for the quarter stood at more than -$32.05 million. ACET stock balance sheet for the recent quarter shows that total liabilities totaled 38.76 million, with total debt at $23.5 million. Shareholders hold equity totaling $42.96 million.
Let’s look briefly at Adicet Bio Inc. (ACET) price momentum from a technical analysis perspective. The 9-day relative strength index as at close on 07 August was 27.61% to suggest the stock is trending oversold, with historical volatility in this time period at 55.63%.
The stock’s 5-day moving average is $2.39, reflecting a -16.10% or -$0.43 change from its current price. ACET is currently trading -33.73% above its 20-day SMA, -71.86% above its 100-day SMA. However, the stock’s current price level is away from the SMA50 by -60.77% and SMA200 by-86.69%.
Stochastic %K and %D was 4.52% and 5.60% and the average true range (ATR) pointed at 0.23. The RSI (14) points at 31.60%, while the 14-day stochastic is at 11.40% with the period’s ATR at 0.27. The stock’s 9-day MACD Oscillator is pointing at -0.15 and -0.27 on the 14-day charts.
Analyst Ratings
In the most recent analyst report for Adicet Bio Inc. (NASDAQ: ACET), JMP Securities downgraded it to a Mkt perform rating. They previously had a Mkt outperform rating on the stock. Analysts offering their rating for ACET stock have a consensus rating for the stock as Overweight. Currently, 0 brokerage advisors rate ACET as a “sell,”, while 4 advise that investors “Hold.” 0 analysts have rated the stock as underweight. 0 rates the stock as overweight while 6 have offered a “buy” rating.
What is ACET’s price target for the next 12 months?
Analysts have a consensus price target ranging from a low of $6.00 and a high of $38.00, with their median price target at $22.50. Looking at these predictions, the average price target given by analysts is for Adicet Bio Inc. (ACET) stock is $21.88.
